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Rehmannia glutinosa (Di-huang) is a widely used traditional
Chinese herb that belongs to the Scrophulariaceae family,
mainly distributing in Liaoning, Hebei, Henan, Shandong, and
Shanxi provinces of China. The roots of R. glutinosa have been
intensively studied and were found to contain diverse
compounds including iridoids [1–3], sesquiterpenes [4–6],
phenylethanoid glycosides [7–9], and triterpene [10]. More-
over, intensive pharmacological investigation revealed its
significant biological properties like anti-diabetes [11,12],
anti-allergy [13], anti-oxidant, and anti-inflammatory activities
[14]. However, very few phytochemical studies of the leaves
of R. glutinosa have been reported so far. As part of an on-
going program to search for bioactive compounds from this
medicinal plant, the 50% aqueous acetone extract of the
air-dried leaves of R. glutinosa was investigated. As a result,terms of the Creative
cted use, distribution,
al author and source
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r B.V. Open access under CC BYthree new ursane-type triterpenes, glutinosalactone A–C (1–3)
were isolated. Their structures (see Fig. 1) were unequivocally
determined by extensive spectroscopic analysis and compari-
son with literature data. The cytotoxic activities of compounds
1–3 against three human cancer cell lines (MCF-7, MG63 and
HepG2) were evaluated. Compound 3 showed cytotoxic
activities with IC50 values of 8.35–39.25 μM. To the best of
our knowledge, this is the second report of triterpenes from
this plant. The isolation, structural elucidation, and cytotoxic-
ities of compounds 1–3 are described herein.2. Experimental
2.1. General
Optical rotation was measured with JASCO P-2000 digital
polarimeter (Jasco, Tokyo, Japan). IR spectra were measured
with a Shimadzu FT-IR 8201 PC spectrometer. 1H-NMR
(500 MHz), 13C-NMR (125 MHz) and 2D NMR were recorded
at room temperature in CD3OD or CDCl3 using Bruker Avance III
500 NMR spectrometer and chemical shifts were given in δ
(ppm) value relative to TMS as internal standard. HR-TOF-MS
was recorded on a Bruker MicrOTOF-Q II spectrometer (Bruker
Daltonics, Germany). HPLC was performed on a Waters license.
Fig. 1. Structures of compounds 1–3.
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connected to a Waters 2998 photodiode array (PDA) detector
(190–800 nm) equipped with a symmetry® C18 column
(250 mm × 4.6 mm I.D. 5 μm) (Waters, Ireland). Column
chromatography was performed on silica gel (160–200 mesh,
Qingdao Marine Chemical Co., Qingdao, China), Toyopearl
HW-40 (TOSOH Corp., Tokyo, Japan), MCI gel CHP-20 and
Diaion HP-20 (Mitsubishi Chemical Corp., Tokyo, Japan),
Sephadex LH-20 (40–70 μm, GE Healthcare Bio-Sciences AB,
USA), Lichroprep RP-18 gel (40–63 μm, Merck, Darmstadt,
Germany). TLC was conducted on self-made silica gel G
(Qingdao Marine Chemical Industry, Qingdao, China) plates
and spots were visualized by spraying with 10% H2SO4 in
ethanol (v/v) followed by heating. The chemical reagents were
supplied by Beijing Chemical Plant (Beijing, China) and Tianjin
NO.3 Reagent Plant (Tianjin, China).
2.2. Plant material
The leaves of R. glutinosa were collected from Jiaozuo,
Henan Province, China, in Oct, 2010, and identified by
Prof. Cheng-MingDong, HenanUniversity of Traditional Chinese
Medicine, China. A voucher specimen (No. 20101101A) has
been deposited in Department of Natural Medicinal Chemistry,
School of Pharmacy, Henan University of Traditional Chinese
Medicine.
2.3. Extraction and isolation
The air-dried leaves of R. glutinosa (3.5 kg) were extracted
with aqueous acetone (50% v/v) for three times (3 × 15 L,
10 min each time) at room temperature. The combined
aqueous acetone extracts (686.5 g) were suspended in H2O,
centrifuged and then subjected to Diaion HP-20 column
(8.0 × 90.0 cm) and successively eluted with H2O, 10%, 20%,
30%, 40%, 80% (v/v) MeOH–H2O, respectively. The 40% MeOH
fraction (16.9 g) was chromatographed on Toyopearl HW-40
and eluted with H2O to afford subfractions 1–8. Subfraction 3
(0.8 g) was subjected to repeating column chromatography
over Toyopearl HW-40 (CHCl3/MeOH, 1:1), silica gel (EtOAc/
EtOH/H2O, 20:2:1), RP-18 (MeOH/H2O, 4:1), MCI gel CHP-20
(MeOH/H2O, 7:3) and Sephadex LH-20 (MeOH/H2O, 7:3) to
yield compound 3 (48 mg). Subfraction 5 (1.3 g) was submit-
ted to MCI gel column chromatography eluting with MeOH/H2O (1:1) and further purified with Toyopearl HW-40 column
(MeOH) to yield compound 1 (42 mg). Subfraction 6 (68 mg)
was subjected to repeating column chromatography on silica
gel (CHCl3/MeOH, 10:1) and further purified with Toyopearl
HW-40 (CHCl3/MeOH, 3:1) to yield compound 2 (36 mg). For
purity determination, the compounds 1–3 were detected at
254 nm on TLC, and the spots were also visualized by spraying
with 10% H2SO4 in ethanol (v/v) followed by heating.
Glutinosalactone A (1): colorless needles; [α]20 D-61.3
(c 0.13, MeOH); IR (KBr) νmax (cm−1): 3436, 2937, 2865,
1735; HR-TOF-MS m/z 525.3187 [M + Na]+ (calcd for
C30H46O6Na, 525.3192); 1H (CD3OD, 500 MHz) and 13C
NMR (CD3OD, 125 MHz) data (see Tables 1 and 2).
Glutinosalactone B (2): colorless needles; [α]20 D-59.5
(c 0.11, MeOH); IR (KBr) νmax (cm−1): 3436, 2938, 2874,
1735; HR-TOF-MS m/z 509.3232 [M + Na]+ (calcd for
C30H46O5Na, 509.3243); 1H (CD3OD, 500 MHz) and 13C
NMR (CD3OD, 125 MHz) data (see Tables 1 and 2).
Glutinosalactone C (3): colorless needles; [α]20 D-13.7
(c 0.09, MeOH); IR (KBr) νmax (cm−1): 3436, 2937, 2865,
1735; HR-TOF-MS m/z 525.3186 [M + Na]+ (calcd for
C30H46O6Na, 525.3192); 1H (CD3OD, 500 MHz) and 13C NMR
(CD3OD, 125 MHz) data (see Tables 1 and 2).2.4. Cytotoxicity assay in vitro
The cytotoxicity assay of compounds 1–3 was evaluated
against MCF-7, MG63 and HepG2 cells by MTT assay. All
the cells were cultured in RPMI 1640 medium (Hyclone,
Logan, UT), and supplemented with 10% fetal bovine serum
(Hyclone, Logan, UT) and antibiotic (100 U/mL penicillin and
100 μg/mL streptomycin). Cells were plated in 96-well
microassay culture plates (1 × 104 cells per well) and grown
at 37 °C for 24 h in a 5% CO2 incubator, and then treated with
these three compounds at various concentrations (0, 1, 10, 25,
50, 100 μM). After 72 h of treatment, 20 μL of 5 mg/mL MTT
solution was added to each well and further incubated for 4 h.
The cells in each well were then solubilized with DMSO (150 μL
for each well). The optical density of each well was then
measured on a microplate spectrophotometer at a wavelength
of 490 nm. The IC50 values were determined by plotting the
percentage viability versus concentration on a logarithmic
graph and reading off the concentration at which 50% of cells
Table 1
1H NMR Data for compounds 1–3 (500 MHz, δ in ppm, J in Hz).
Position 1a 2a 3b
1 1.18 m, 1.30 m 1.28 m, 1.37 m 1.22 m, 1.30 m
2 1.75 m, 2.20 dd
(13.1, 4.2)
1.42 m, 1.91 m 1.68 m, 2.79 m
3 3.76 br.s 3.34 br.s 3.39 br.s
5 1.39 m 1.37 m 1.19 m
6 1.40c, 1.52 m 1.41c, 1.43 m 1.38 m, 1.47 m
7 1.43 m,1.57 m 1.44 m, 1.50 m 1.41 m, 1.49 m
9 2.23 m 2.24 m 1.46 m
11 1.65 m, 1.95 m 1.69 m, 1.91 m 2.02 dd (16.0, 6.3),
1.77 m
12 5.99 br.s 6.00 br.s 3.78 d (4.2)
15 1.41 m, 2.35 ddd
(13.2, 13.2, 4.1)
1.45 m, 2.37 ddd
(13.2, 13.2, 4.1)
1.48 m, 1.89 m
16 1.42 m, 2.43 ddd
(13.2, 13.2, 4.1)
1.43 m, 2.40 ddd
(13.2, 13.2, 4.1)
1.42 m, 2.36 m
18 1.89 s 1.93 s 1.82 s
21 1.30 m, 1.55 m 1.29 m, 1.51 m 1.18 m, 1.63 m
22 1.85 m, 2.14 m 1.97 m, 2.13 m 1.65 m, 2.30 m
23 1.03 s 0.83 s 0.81 s
24 3.42 d (11.0),
3.68 d (11.0)
0.93 s 0.92 s
25 0.92 s 0.95 s 0.88 s
26 0.81 s 0.85 s 0.91 s
27 1.18 s 1.18 s 1.17 s
29 1.37 s 1.37 s 1.32 s





a Recorded in CD3OD.
b Recorded in CDCl3.
c Multiplicity not clear for some signals due to overlapping.
Table 2
13C NMR Data for compounds 1–3 (125 MHz).
Position 1a (DEPT) 2a (DEPT) 3b (DEPT)
1 34.0 (CH2) 34.0 (CH2) 32.6 (CH2)
2 26.0 (CH2) 26.1 (CH2) 23.9 (CH2)
3 71.3 (CH) 76.9 (CH) 75.7 (CH)
4 43.9 (C) 43.1 (C) 37.1 (C)
5 51.0 (CH) 51.0 (CH) 48.7 (CH)
6 19.8 (CH2) 19.6 (CH2) 17.9 (CH2)
7 34.6 (CH2) 34.2 (CH2) 33.2 (CH2)
8 41.8 (C) 41.2 (C) 38.9 (C)
9 50.8 (CH) 50.3 (CH) 43.9 (CH)
10 38.3 (C) 38.3 (C) 37.2 (C)
11 25.5 (CH2) 25.5 (CH2) 20.9 (CH2)
12 127.0 (CH) 127.1 (CH) 57.2 (CH)
13 135.9 (C) 135.9 (C) 66.2 (C)
14 43.0 (C) 41.7 (C) 42.0 (C)
15 26.7 (CH2) 26.7 (CH2) 25.1 (CH2)
16 26.4 (CH2) 26.4 (CH2) 24.1 (CH2)
17 41.9 (C) 38.5 (C) 39.7 (C)
18 48.6 (CH) 48.4 (CH) 42.8 (CH)
19 73.8 (C) 73.8 (C) 74.5 (C)
20 88.1 (C) 88.1 (C) 85.2 (C)
21 25.8 (CH2) 25.8 (CH2) 24.8 (CH2)
22 25.1 (CH2) 25.0 (CH2) 27.0 (CH2)
23 22.8 (CH3) 22.7 (CH3) 22.0 (CH3)
24 66.2 (CH2) 28.9 (CH3) 28.2 (CH3)
25 16.2 (CH3) 15.9 (CH3) 15.3 (CH3)
26 16.5 (CH3) 16.5 (CH3) 16.4 (CH3)
27 23.4 (CH3) 23.5 (CH3) 17.8 (CH3)
28 181.0 (C) 181.0 (C) 177.1 (C)
29 25.8 (CH3) 25.8 (CH3) 26.5 (CH3)
30 63.6 (CH2) 63.6 (CH2) 63.2 (CH2)
a Recorded in CD3OD.
b Recorded in CDCl3.
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repeated three times to get the mean values.
3. Results and discussion
Compound 1 was obtained as colorless needles. Its molec-
ular formula was deduced to be C30H46O6 by the HR-TOF-MS at
m/z 525.3187 [M + Na]+ (calcd for C30H46O6Na, 525.3192).
The IR spectrum exhibited absorptions at 3436 and 1735 cm−1
indicating the existence of hydroxyl and δ-lactone functional-
ities. The 1H NMR spectrum of 1 showed signals attributable to
one olefin [δH 5.99 (br.s##)], one oxymethine [δH 3.76 (br.s)],
two oxymethylene [δH 3.76 and 3.84 (1H each, d, J = 11.0 Hz),
3.68 and 3.42 (1H each, d, J = 11.0 Hz)] and five tertiary
methyl groups (δH 0.81, 0.92, 1.03, 1.18 and 1.37). The 13C NMR
and DEPT spectra revealed 30 signals including a lactone
carbonyl carbon (δC 181.0), a pair of olefinic carbons (δC 135.9
and 127.0), two oxyquaternary carbons (δC 88.1 and 73.8), one
oxymethine carbon (δC 71.3), two oxymethylene carbons
(δC 66.2 and 63.6), and five methyl carbons (δC 25.8, 23.4, 22.8,
16.5, and 16.2). These NMR spectral data closely resembled
those of glutinolic acid,whichwas reported as a polyoxygenated
triterpene from R. glutinosawith a pentahydroxy-urs-12-en-oic
acid skeleton bearing an α-hydroxyl at C-19 [10]. This pre-
sumption was further corroborated by the HMBC long-range
correlations, in which the proton signals at δH 3.68 (Ha-24) and
δH 3.42 (Hb-24) correlated with δC 71.3 (C-3), 51.0 (C-5) and δC
43.9 (C-4), the proton signals at δH 3.84 (Ha-30) and δH 3.76
(Hb-30) correlated with δC 88.1 (C-20) and δC 73.8 (C-19), and
the methine proton signal at δH 1.89 (H-18) correlated with δC
135.9 (C-13), 127.0 (C-12), 88.1 (C-20) and 73.8 (C-19) (see
Fig. 2). In comparison of the NMR data of 1 to those of glutinolic
acid (3α,19α,20β,24,30-pentahydroxyurs-12-en-28 oic acid),
the main difference in 1 was the presence of an δ-lactone ring
between C-20 and C-18 [15–18]. Thiswas further verified by the
expected upfield shifts for C-17 (−6.5 ppm), C-21 (−1.4 ppm),
C-22 (−7.6 ppm), and C-28 (−2.0 ppm), downfield shift for
C-20 (+11.5 ppm) and one more degree of unsaturation than
those of glutinolic acid.
The relative configuration of 1was determined based on a
NOESY experiment. The NOE correlations (see Fig. 3) were
observed between H-3α and H3-23, H3-23 and H-5, H-12
and H-18, H-18 and H3-29, H-12 and H3-26, indicating a
β-hydroxy group at C-3 [19,20] and a β-orientation for H-29.
The 1H and 13C NMR data were fully assigned by the 1H-1H
COSY, HSQC, HMBC and NOESY spectra (see Tables 1 and 2).
Thus, the structure of compound 1 was elucidated to be
3β,19α,20β,24,30-pentahydroxyurs-12-en-28 oic acid δ-lactone,
and named as glutinosalactone A.
Compound 2 was obtained as colorless needles. Its molec-
ular formula was deduced to be C30H46O5 from the HR-TOF-MS
atm/z 509.3232 [M + Na]+ (calcd for C30H46O5Na, 509.3243).
The IR spectrum exhibited absorptions at 3437 cm−1 and
1735 cm−1 indicating the presence of hydroxyl and δ-lactone
functionalities. In comparison of the NMR data of 2 to those
of 1 (see Tables 1 and 2), these data revealed that the
oxymethylene at C-4 of 1 was replaced by methyl in 2, which
was confirmed by the HMBC correlations from H-24 (δH 0.93)
to C-3 (δC 76.9) and C-4 (δC 43.1), and from H-23 (δH 0.83) to
C-3 (δC 76.9) and C-4 (δC 43.1) (see Fig. 2). All the proton and
carbon signals of compound 2were assigned using the 2DNMR
Fig. 2. Key HMBC (H → C) correlations of compounds 1–3.
Fig. 3. Key NOESY correlations of compounds 1–3.
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tetrahydroxyurs-12-en-28 oic acid δ-lactone, and named as
glutinosalactone B.
Compound 3 was obtained as colorless needles. Its molec-
ular formula was deduced to be C30H46O6 from the HR-TOF-MS
atm/z 525.3186 [M + Na]+ (calcd for C30H46O6Na, 525.3192).
The IR spectrum exhibited absorptions at 3436 cm−1 and
1735 cm−1 indicating the presence of hydroxyl and δ-lactone
functionalities. The 1H and 13C NMR data of 3 were similar to
those of 2 (see Tables 1 and 2). Themain difference in 3was the
absence of 13C NMR signals at C-12 and C-13 of an olefinic bond
and the presence of one oxyquaternary carbon (δC 66.2) and
one oxymethine carbon (δC 57.2). This revealed that 3 was an
oxide derivative of 2. By comparing the NMR data with those
reported similar compounds [21–24], an epoxy ring between
C-12 and C-13 was expected to be the most plausible
explanation. This structural variation was confirmed by the
HMBC correlations from H-11 (δH 2.02, 1.77) to C-12 (δC 57.2)
and C-13 (δC 66.2), and from H-18 (δH 1.82) to C-12 (δC 57.2),
C-13 (δC 66.2), C-19 (δC 74.5) and C-20 (δC 85.2) (see Fig. 2). The
NOESY correlations (see Fig. 3) between H3-26 and H-12, H-12
andH-18,H-18 andH3-29 indicated that the epoxy ringbetween
C-12 and C-13 occupied the α-face of the molecule. Based on
the above interpretation, the structure of 3 was determined to
be 12α,13α-epoxy-3β,19α,20β,30-tetrahydroxyurs-28 oic acid
δ-lactone, and named as glutinosalactone C.
All compounds were evaluated for their cytotoxicity
against MCF-7, MG63 and HepG2 cell lines by MTT assay in
vitro. Compound 3 exhibited cytotoxicity against MCF-7
(IC50 = 8.35 ± 0.16 μM), MG63 (IC50 = 39.25 ± 0.21 μM),
HepG2 (IC50 = 17.29 ± 2.16 μM), while compounds 1 and 2
showed no cytotoxicities (IC50>40 μM).Acknowledgements
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Appendix A. Supplementary data
The 1D NMR, 2D NMR, HR-TOF-MS and IR spectra for
compounds 1–3 are available in the Supplementary data.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.fitote.2013.05.013.
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